DNA

Ginkgo Bioworks Holdings, Inc.

6.08

USD

DNA Earnings Reports

Positive Surprise Ratio

DNA beat 7 of 18 last estimates.

39%

Next Report

Date of Next Report

May 07, 2026

Estimate for Q1 26 (Revenue/ EPS)

$41.86M

-$1.09

Implied change from Q4 25 (Revenue/ EPS)

+25.36%

-22.70%

Implied change from Q1 25 (Revenue/ EPS)

-13.36%

-35.12%

Ginkgo Bioworks Holdings, Inc. earnings per share and revenue

On Feb 26, 2026, DNA reported earnings of -1.41 USD per share (EPS) for Q4 25, beating the estimate of -1.46 USD, resulting in a 4.06% surprise. Revenue reached 33.40 million, compared to an expected 37.46 million, with a -10.85% difference. The market reacted with a +3.52% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -1.09 USD, with revenue projected to reach 41.86 million USD, implying an decrease of -22.70% EPS, and increase of 25.36% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Ginkgo Bioworks Holdings, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Ginkgo Bioworks Holdings, Inc. reported EPS of -$1.41, beating estimates by 4.06%, and revenue of $33.40M, -10.85% below expectations.

How did the market react to Ginkgo Bioworks Holdings, Inc.'s Q4 2025 earnings?

The stock price moved up 3.52%, changed from $9.38 before the earnings release to $9.71 the day after.

When is Ginkgo Bioworks Holdings, Inc. expected to report next?

The next earning report is scheduled for May 07, 2026.

What are the forecasts for Ginkgo Bioworks Holdings, Inc.'s next earnings report?

Based on -- analysts, Ginkgo Bioworks Holdings, Inc. is expected to report EPS of -$1.09 and revenue of $41.86M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.